SLN
Silence Therapeutics Plc - ADR

450
Mkt Cap
$250.81M
Volume
307,274.00
52W High
$7.91
52W Low
$1.97
PE Ratio
-2.82
SLN Fundamentals
Price
$5.31
Prev Close
$5.47
Open
$5.42
50D MA
$5.48
Beta
0.67
Avg. Volume
174,466.37
EPS (Annual)
-$1.88
P/B
4.03
Rev/Employee
$6,367.11
$202.21
Loading...
Loading...
News
all
press releases
Silence Therapeutics (NASDAQ:SLN) Rating Increased to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised shares of Silence Therapeutics to a "strong-buy" rating in a report on Wednesday...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
What is HC Wainwright's Estimate for SLN FY2030 Earnings?
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for Silence Therapeutics in a research report issued...
MarketBeat·11d ago
News Placeholder
Silence Therapeutics' (SLN) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday...
MarketBeat·14d ago
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Analysts
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been assigned an average recommendation of "Hold" from the seven research firms that are presently covering the firm...
MarketBeat·18d ago
News Placeholder
Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results, Beats Estimates By $0.06 EPS
Silence Therapeutics (NASDAQ:SLN - Get Free Report) released its earnings results on Thursday. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by...
MarketBeat·22d ago
News Placeholder
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·22d ago
News Placeholder
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year...
Business Wire·22d ago
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six brokerages that are currently covering the company, MarketBeat Ratings...
MarketBeat·1mo ago
News Placeholder
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1% - Here's What Happened
Silence Therapeutics (NASDAQ:SLN) Trading Down 5.1% - Time to Sell...
MarketBeat·2mo ago
News Placeholder
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat...
MarketBeat·2mo ago
<
1
2
...
>

Latest SLN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.